Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control

NCT00621140 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

503

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: linagliptin
DRUG: placebo

Sponsor

Boehringer Ingelheim